Jazz Pharmaceuticals plc (JAZZ) stock — is it a good business?

Jazz Pharmaceuticals plc (JAZZ) stock — is it a good business? — InspectStocks

How it makes money

Xywav for narcolepsy and idiopathic hypersomnia41%
Epidiolex for seizures associated with certain rare epilepsy conditions26%
Rylaze for patients with leukemia or lymphoma who cannot take a common asparaginase medicine10%
Zepzelca for small-cell lung cancer8%
Xyrem for narcolepsy4%

Shares of revenue are estimates for 2025, not figures from a filing.

Competes with

What it sells6

Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.

Show 3 more

Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.

Who buys it5

Patients use Jazz's medicines under prescriptions from healthcare professionals.
ESSDS is the certified specialty pharmacy that receives U.S. Xywav and Xyrem and ships them directly to patients.
Onco360 is the certified specialty pharmacy that ships Modeyso directly to patients in the United States.

Show 2 more

Specialty pharmacies and distributors supply Epidiolex to patients and healthcare providers.
McKesson, Cencora and Cardinal distribute Zepzelca, Rylaze, Ziihera and other medicines to hospitals and healthcare customers.

What it stands on, and what could break it

What the business leans on

1The business continues to depend substantially on Xywav sales and on maintaining physician and patient use and insurance coverage for it.
2Xywav and Xyrem require a restricted distribution system: prescriptions must go through a certified pharmacy under a Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy.
3Jazz relies on outside manufacturers and suppliers for many medicines. Patheon supplies several products, and the company identifies sole-source suppliers for products including Modeyso and Vyxeos.
4Sales depend on regulatory approvals, continued access to reimbursement from insurers and pharmacy benefit managers, and the results of required follow-up trials for some accelerated approvals.

What could go wrong

1Generic high-sodium oxybate medicines, branded alternatives and new sleep-disorder treatments may reduce demand for Xywav and Xyrem or lead insurers to offer less favorable coverage.
2Epidiolex sales depend on continued prescribing and insurance reimbursement; the medicine also faces competition from other seizure treatments and could face generic competition under patent-settlement terms or earlier in certain circumstances.
3Some cancer medicines have accelerated or conditional approvals that depend on follow-up trials; unsuccessful trials or regulatory action could restrict or remove an approval, as happened when the second-line small-cell lung cancer indication for Zepzelca was removed in September 2026.

Full financial statements →

About Jazz Pharmaceuticals plc

Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).

Head office: Dublin, Ireland
Founded: 2003
Employees: 2,890 (December 31, 2025, high)
Listed on: Nasdaq
Financial year ends: December 31

Built from Jazz Pharmaceuticals plc’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Keep exploring

The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

How it makes money

Xywav for narcolepsy and idiopathic hypersomnia41%
Epidiolex for seizures associated with certain rare epilepsy conditions26%
Rylaze for patients with leukemia or lymphoma who cannot take a common asparaginase medicine10%
Zepzelca for small-cell lung cancer8%
Xyrem for narcolepsy4%

Shares of revenue are estimates for 2025, not figures from a filing.

Competes with

What it sells6

Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.

Show 3 more

Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.

Who buys it5

Patients use Jazz's medicines under prescriptions from healthcare professionals.
ESSDS is the certified specialty pharmacy that receives U.S. Xywav and Xyrem and ships them directly to patients.
Onco360 is the certified specialty pharmacy that ships Modeyso directly to patients in the United States.

Show 2 more

Specialty pharmacies and distributors supply Epidiolex to patients and healthcare providers.
McKesson, Cencora and Cardinal distribute Zepzelca, Rylaze, Ziihera and other medicines to hospitals and healthcare customers.

What it stands on, and what could break it

What the business leans on

1The business continues to depend substantially on Xywav sales and on maintaining physician and patient use and insurance coverage for it.
2Xywav and Xyrem require a restricted distribution system: prescriptions must go through a certified pharmacy under a Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy.
3Jazz relies on outside manufacturers and suppliers for many medicines. Patheon supplies several products, and the company identifies sole-source suppliers for products including Modeyso and Vyxeos.
4Sales depend on regulatory approvals, continued access to reimbursement from insurers and pharmacy benefit managers, and the results of required follow-up trials for some accelerated approvals.

What could go wrong

1Generic high-sodium oxybate medicines, branded alternatives and new sleep-disorder treatments may reduce demand for Xywav and Xyrem or lead insurers to offer less favorable coverage.
2Epidiolex sales depend on continued prescribing and insurance reimbursement; the medicine also faces competition from other seizure treatments and could face generic competition under patent-settlement terms or earlier in certain circumstances.
3Some cancer medicines have accelerated or conditional approvals that depend on follow-up trials; unsuccessful trials or regulatory action could restrict or remove an approval, as happened when the second-line small-cell lung cancer indication for Zepzelca was removed in September 2026.

Full financial statements →

About Jazz Pharmaceuticals plc

Head office: Dublin, Ireland
Founded: 2003
Employees: 2,890 (December 31, 2025, high)
Listed on: Nasdaq
Financial year ends: December 31

How it makes money

Competes with

What it sells6

Who buys it5

What it stands on, and what could break it

What the business leans on

What could go wrong

About Jazz Pharmaceuticals plc

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells6

Who buys it5

What it stands on, and what could break it

What the business leans on

What could go wrong

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Biotech

Growth & cash — 5 of 5

Business trend

Share price and grade over time

How it makes money

Competes with

What it sells6

Who buys it5

What it stands on, and what could break it

What the business leans on

What could go wrong

About Jazz Pharmaceuticals plc

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells6

Who buys it5

What it stands on, and what could break it

What the business leans on

What could go wrong

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc

Past performance

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Biotech

Growth & cash — 5 of 5

Business trend

Share price and grade over time